(Q64149709)
Statements
GECKO (English)
0 references
A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis (English)
0 references
25 March 2019
0 references
January 2020
0 references
60
0 references
18 year
0 references
65 year
0 references